Probiotec announced an increase of 17.4% to A$214.0 million in its FY underlying sales revenue from ordinary activities.

Despite the uptick in sales, the company reported an underlying net profit after tax for the year reduced by 3.4% to A$13.0 million.

Additionally, Probiotec (ASX:PBP) declared a final dividend of 3.5 AU cents per ordinary share, fully franked.

Probiotec is a prominent pharmaceutical company specializing in developing and manufacturing a wide range of over-the-counter, prescription, and veterinary products.